Verrica Pharmaceuticals Initiates Phase 3 Trial for VP-102 in Common Warts Treatment
核心洞察
Verrica Pharmaceuticals dosed the first patient in December 2025 for a global Phase 3 trial evaluating VP-102 for common warts (搜索), a condition affecting approximately 22 million people in the United States.
The Phase 3 program is supported by Phase 2 COVE-1 trial results showing 51% of patients achieved complete wart clearance at day 84, with no serious adverse events reported.
VP-102 could become the first FDA-approved therapy specifically for common warts (搜索), addressing a significant unmet medical need in dermatology with potential multibillion-dollar market opportunity.
Verrica Pharmaceuticals Inc has initiated a global Phase 3 clinical development program for VP-102 (YCANTH) in the treatment of common warts (搜索), with the first patient dosed in December 2025. This milestone represents a significant expansion of the clinical development strategy for VP-102 beyond its currently approved indication for molluscum contagiosum (搜索).
Addressing a Major Unmet Medical Need
Common warts (搜索) (verruca vulgaris) are benign epidermal proliferations caused by human papillomavirus (搜索) (HPV (搜索)) infection that affect an estimated 22 million individuals in the United States alone. Children represent approximately half of all patients seeking treatment for this condition. Despite this high prevalence, there are currently no therapies approved by the US FDA specifically for the treatment of common warts.
Current management typically relies on off-label or destructive approaches such as cryotherapy, salicylic acid preparations, curettage, or immunomodulatory techniques. These treatments can be painful, require multiple visits, and yield variable outcomes, highlighting the clinical need for standardized, approved pharmacologic therapies suitable for both pediatric and adult populations.
Phase 2 Foundation for Phase 3 Development
The Phase 3 program is informed by positive results from the Phase 2 COVE-1 clinical trial, an open-label study that evaluated the safety and efficacy of VP-102 in patients with up to six common warts (搜索). The trial included two cohorts, with the primary efficacy analysis conducted at day 84 and extended follow-up through day 147.
Topline results from cohort 2 demonstrated that 51% of treated subjects (18 of 35) achieved complete clearance of all treatable warts at day 84. Assessments were conducted across study visits over a 12-week treatment period. Reported adverse events were primarily localized cutaneous reactions, consistent with the known pharmacologic effects of cantharidin. Notably, no serious adverse events were observed in the study.
Strategic Partnership and Financial Structure
The global Phase 3 program is being conducted in collaboration with Torii Pharmaceutical (搜索), Verrica's partner in Japan. Under the collaboration terms, Torii will share development costs on a 50/50 basis and fund the first $40 million of trial expenses, representing approximately 90% of the current projected trial budget. Verrica's portion of costs is expected to be offset through future milestones and royalties related to VP-102 in Japan.
This cost-sharing arrangement reduces near-term financial risk for Verrica while supporting a development program intended to support potential regulatory submissions in multiple regions, including the United States, Japan, and potentially the European Union.
VP-102 Drug-Device Platform
VP-102 is a proprietary drug-device combination product containing a pharmaceutical-grade, GMP-controlled formulation of cantharidin, delivered through a single-use applicator designed to allow precise topical dosing and targeted lesion application. Cantharidin has a long history of use in dermatology but had not been available as an FDA-approved, standardized product until recently.
VP-102 is currently approved in the United States for the treatment of molluscum contagiosum (搜索) in adult and pediatric patients aged 2 years and older. This approval was based on two Phase 3 randomized clinical trials involving approximately 500 patients, which demonstrated safety and efficacy for complete lesion clearance. The product is administered by healthcare professionals and is widely covered by insurance plans in the US, with patient assistance programs available for eligible individuals.
Commercial and Clinical Implications
If successful, VP-102 could become the first therapy approved in both the US and Japan specifically for the treatment of common warts (搜索). From a clinical perspective, an approved, standardized, healthcare professional-administered therapy could offer a more predictable and potentially less burdensome treatment option compared with existing off-label approaches.
"The clinically meaningful activity observed for the primary endpoint of complete clearance in the Phase 2 COVE-1 study provides strong evidence that YCANTH has the potential to become the first therapy ever approved in both the United States and Japan for the treatment of common warts (搜索)," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica.
From a market standpoint, Verrica estimates that the prevalence of common warts (搜索) and the absence of approved therapies represent what the company believes could be a multibillion-dollar commercial opportunity. The company anticipates potential synergies with its existing VP-102 commercial infrastructure for molluscum contagiosum (搜索), given overlapping prescriber bases and patient populations, particularly in pediatric dermatology. Verrica believes that the common wart patient opportunity in the European Union is comparable to that in the United States.
The dosing of the first patient in the global Phase 3 program marks a significant step in the clinical development of VP-102 for common warts (搜索), reflecting broader efforts within dermatology to move beyond empiric and destructive treatments toward standardized, evidence-based therapies for highly prevalent skin conditions.